Empyrean Capital Partners, LP Atai Life Sciences N.V. Transaction History
Empyrean Capital Partners, LP
- $1.39 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding ATAI
# of Institutions
97Shares Held
12.8MCall Options Held
9.2KPut Options Held
118K-
Walleye Capital LLC Plymouth, MN2.76MShares$3.15 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.72MShares$3.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$1.49 Million0.0% of portfolio
-
Brown University719KShares$819,0890.39% of portfolio
-
Two Sigma Investments, LP New York, NY717KShares$817,5290.0% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $189M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...